# Kudzu-the Miracle Vine

Kathy Abascal, B.S., J.D., R.H. (AHG), and Eric Yarnell, N.D., R.H. (AHG)

### Abstract

The clinical uses of, and research on, *Pueraria montana* var *lobata* (kudzu, kuzu, *ge gen*) and related species are reviewed in this article. Kudzu's applications in alcoholism and the herb's ability to lessen the negative effects of alcohol are covered as are the herb's applications for treating menopausal symptoms, osteoporosis, diabetes, stroke, and cardiovascular disease as well as how kudzu acts as a hepatoprotectant.

## Introduction

*Pueraria montana* var *lobata* (formerly *P. lobata*), along with related species (kudzu), was one of first plants mentioned in Traditional Chinese Medicine (TCM). In TCM, the root and the flower were used to treat the ill effects of alcohol, fever, headache; to relieve stiffness in the back and neck; and to treat the early stages of measles. Today, in Asia, kudzu is commonly used to treat stroke, heart disease, and diabetes. Western use of kudzu is largely limited to treating drinking problems and menopausal symptoms.

Kudzu was first introduced to the United States in 1876 and rapidly became a popular garden plant owing to its large leaves and fragrant flowers. During the Depression, the government paid to have kudzu planted to stabilize the soil,<sup>1</sup> and it was then called "the miracle vine." Kudzu, however, under the right conditions, can grow a foot a day and, thus, soon became invasive. Its invasiveness gained it new common names such as "mile-aminute vine," "foot-a-night-vine," and "the vine that ate the South."

Although clinical studies on kudzu are sparse, the plant has interesting properties that suggest that practitioners should be using kudzu to treat a greater variety of ailments. If its potential benefits are investigated and confirmed, the plant will once again be known as "the miracle vine."

## Kudzu Species and Constituents

Many different species of kudzu are used in Asia. In China, *P. montana* (also known as *P. thunbergiana*) and *P. thomsonii* are used interchangeably. *P. mirifica* and *P. tuberosa* are also used frequently. There are subtle differences between the species but these are not well-defined. For instance, *P. montana* has shown a more potent antioxidant effect than *P. thomsonii* has and contains higher amounts of important isoflavones.<sup>2</sup> In a screening, *P. montana* flower had a higher estrogenic potency than its root did.<sup>3</sup>

Kudzu contains a number of strong phytoestrogenic compounds in both its roots (puerarin and daidzin) and flowers (kakkalide and tectoridin). Human intestinal bacteria hydrolyze these isoflavones, resulting in metabolites (daidzein, irisolidone, and tectorigenin) that have more potent estrogenic activity than their precursors.<sup>4,5</sup>

## Alcoholism and After-Effects of Intoxication

Kudzu is used in Western botanical medicine to treat chronic drinking problems, and we have used the herb successfully for this. (See box entitled A Kudzu Case Study.) It is also used to prevent the negative aftereffects of intoxication. Unfortunately, there are only two clinical studies on kudzu and drinking. In the first clinical study, kudzu appeared to be ineffective.<sup>6</sup> This study, however, has been severely criticized because both the active and the control group were virtually completely abstinent and "under the conditions of this study, no drug would have been effective because the control group was so good."<sup>7</sup> In addition, the researchers ignored the fact that only 1 person withdrew from the kudzu group while 10 patients who were taking the placebo withdrew.

In the second clinical study, heavy drinkers (N = 14) were treated with placebo or kudzu (two 500-mg capsules 3 times per day\*) for 7 days.<sup>8</sup> The patients were allowed to drink their preferred brands of beer, and their drinking behavior was monitored. Kudzu significantly reduced the number of beers consumed. It also significantly increased the time it took to consume each beer. Kudzu appeared to prolong the acute effects of the first drink, thereby reducing the desire for additional alcohol. Although there was a significant change in drinking patterns, the magnitude of the decrease in intake was modest.<sup>8</sup> This study supports the traditional use of kudzu to prevent intoxication and after-effects.<sup>7</sup>

In animals, kudzu and its constituents show a consistent ability to inhibit alcohol preference effectively, a preference that returns when the kudzu is discontinued.<sup>9–12</sup> Studies also sup-

<sup>\*</sup>The capsules contained 19 percent puerarin, 4 percent daidzin, and 2 percent daidzein.

port the use of kudzu to thwart the negative effects of alcohol. Kudzu appears to alleviate the negative effects of alcohol intake by enhancing lipid metabolism and the hepatic antioxidant defense system.<sup>13</sup> Kudzu counteracts alcohol-induced decreases in Fos-positive cells in the brain, a measurement of alcohol's ability to cause a loss of neurons.<sup>14</sup>

Kudzu flowers increased the elimination of acetaldehyde, which may help prevent flushing, palpitation, headache, and other symptoms associated with excessive alcohol intake.<sup>15,16</sup> One study, however, showed that puerarin, daidzin, and daidzein had no effect on aldehyde dehydrogenase but they did shorten alcohol-induced sleep time and caused blood alcohol levels to peak later and lower.<sup>10</sup>

Kudzu crude extract and puerarin both produced neuroprotective effects against developmental ethanol exposure in vitro,<sup>17</sup> and kudzu flowers had an ameliorating effect on the ethanol-induced impairment of both memory registration and retrieval in mice.<sup>18</sup>

#### Menopause and Osteoporosis

Kudzu contains a number of strong phytoestrogenic compounds. While kudzu is often used by botanical practitioners to treat perimenopausal symptoms, good clinical studies are lacking. Kudzu is of particular interest in menopause because preliminary studies show that the plant protects the body against bone loss and appears to promote bone formation. If this is verified in clinical trials, kudzu may be a safe and effective treatment for osteoporosis.

Only three small clinical trials were located on kudzu in menopause. In the first, 25 menopausal women who had severe hot flashes and night sweats used isoflavones from kudzu and *Trifolium pratense* (red clover) along with other nutrients. The women's hot flashes decreased and their scores on a subjective assessment of quality of life improved, while the markers for cardiovascular disease improved somewhat, and markers of breast cancer risk improved significantly, suggesting that kudzu may help manage symptoms such as hot flashes and offer some protection against other diseases associated with menopause.<sup>19</sup>

In the second trial, 37 pre- and postmenopausal women with hot flashes, night sweats, and urogenital and psychologic symptoms took kudzu capsules (50 or 100 mg per capsule) once daily for 6 months. The patients' scores on a modified Greene climacteric scale decreased in both groups. However, while the treatment alleviated climacteric symptoms, the results were less positive in women who had anemia and abnormal liver profiles.<sup>20</sup>

In the third trial, 127 postmenopausal women took hormone replacement therapy (HRT), kudzu (containing 100 mg isoflavone), or no treatment for 3 months. Kudzu had no significant effect on follicular stimulating hormone (FSH) or luteinizing hormone (LH), but kudzu did improve flexible thinking in the Mini-Mental State examination.<sup>21</sup> This improvement was supported by an animal study in which puerarin (100 mg per kg) administered long term to ovariectomized mice ameliorated learning and memory deficits by normalizing levels of glutamate and gamma-aminobutyric acid (GABA).<sup>22</sup>

*Pueraria montana* var *lobata* (kudzu). Drawing © by Eric Yarnell, N.D., R.H. (A.H.G.).

Animal studies suggest that kudzu can moderate menopausal hormone imbalances. In one study, naturally menopausal monkeys were given various doses of kudzu. The lowest dose (10 mg per day) reduced FSH beginning on day 15 in a third of the animals while the higher doses (100 and 1000 mg per day) decreased FSH levels throughout the experiment. After treatment, FSH levels continued to decrease for 5–20 days in these animals. The lowest dose decreased LH throughout treatment in a third of the animals while the higher doses prominently decreased LH beginning on day 10, and the effect persisted up to 30 days post-treatment.<sup>23</sup>

#### **Bone Loss in Aging**

Bone loss in menopausal women is a significant problem. Kudzu contains high amounts of isoflavones known to prevent bone loss induced by estrogen deficiency. In one study of menopausal monkeys, kudzu (1000 mg per day) decreased serum parathyroid and calcium levels, indicating an ability to ameliorate bone loss.<sup>24</sup>

In ovariectomized rats, kudzu significantly inhibited the induced total femoral bone mineral density (BMD) reduction at the low dose (5 percent of diet) and completely prevented it at the middle dose (10 percent of diet). Intake of the middle dose completely prevented a decrease in trabecular bone volume and thickness. Intake of the high dose (20 percent of diet) further increased bone volume and thickness. In this study, kudzu did not affect uterine weight, which declined.<sup>25</sup>

Kudzu had a similar effect in orchidectomized mice. The decrease in femur BMD in the control group was completely inhibited by kudzu as 10 percent of their diet. The high dose (20 percent of diet) significantly increased BMD with a potency sim-

## A Kudzu Case Study

The patient was a 56-year-old man with cirrhosis secondary to hepatitis C and excessive alcohol ingestion, osteoarthritis, depression, and one episode 4 years ago of bleeding esophageal varices requiring hospitalization. He had struggled unsuccessfully to stop drinking. The following herbal formula was prescribed for him (at a dose of I tsp three times per day):

- Schisandra chinensis (schisandra)—fruit glycerite for cirrhosis and stress, 20%
- Centella asiatica (gotu kola)—whole plant glycerite for cirrhosis, 15%
- Taraxacum officinale (dandelion)—root glycerite for cirrhosis, 15%
- Mahonia aquifolium (Oregon grape)—root glycerite for cirrhosis, 9%
- Picrorhiza kurroa (kutki)-root fluid extract as an antiviral, 9%
- Astragalus membranaceous (astragalus)—root glycerite as an adaptogen, 9%
- Glycyrrhiza glabra (licorice)—root fluid extract for cirrhosis, stress, flavor, synergizing effects, and as an antiviral, 9%
- Pueraria montana (kudzu)—root glycerite for alcoholism, 5%
- Hypericum perforatum (St. John's wort)—herb glycerite for depression and as an antiviral, 5%
- Ceanothus greggii (red root)-tincture as an abdominal lymphatic, 4%
- Aconitum carmichaelii (Sichuan aconite)—prepared root tincture for pain, 1%

Although the kudzu component of the formula was relatively modest, the patient was able to stop drinking and stated he has had little desire for alcohol since he started the formula. He has only drunk on two occasions in the 8 months since he started the formula. Although his herbal formula does contain a small amount of alcohol, it does not seem to have caused him any ongoing liver problems or to have contributed to his drinking problem. His depression has improved dramatically, and his osteoarthritis and other pains have been reduced significantly. His serum liver enzymes have been improved and his cirrhotic symptoms have also been steadily reduced.

ilar to that of estradiol, suggesting the potential use of kudzu to prevent osteoporosis in elderly men with hypogonadism.<sup>25</sup>

In vitro experiments confirm that kudzu's isoflavones have a positive effect on bone. Puerarin stimulated cell proliferation, differentiation, maturation, and mineralization of rat osteoblasts,<sup>26</sup> and another study showed that kudzu enhanced many factors, including mineralization in bone cells, suggesting an ability to stimulate osteoblastic bone formation.<sup>27</sup>

## **Benefits for Patients with Stroke**

In 1998, more than 11 million persons experienced stroke in the United States.<sup>28</sup> This is an enormous health issue that kudzu may help address.

In China, subarachnoid hemorrhages caused by aneurysms are treated with surgery after rupture and by calcium antagonists. Herbs are often included in treatment plans, and kudzu (as a crude extract, in formulas or as an isolated extract, usually puerarin) is said to have been proven to be beneficial both to prevent and treat this disorder.<sup>29</sup> In a study of vascular dementia, a Chinese formula containing kudzu was compared with the Western drug nimodipine at 2 mg per kg per day.<sup>†</sup> The formula improved learning ability and memory compared with controls and was more effective than nimodipine for improving spatial discrimination.<sup>30</sup>

Cerebral infarction is an ischemic condition that results in localized brain tissue death and usually a persistent focal neurologic deficit. Kudzu is commonly included as part of the treatment for this disorder in Asia, and 14 clinical trials (N = 1141) on the clinical use of kudzu for cerebral infarction were analyzed in a recent review. While the methodological quality of the trials was deemed to be poor, the review authors concluded that kudzu may improve the short-term neurologic deficit caused by cerebral infarction.<sup>31</sup>

The formula *Chungpesagantang* is used in Korea for patients who have stroke and for rats with inhibited platelet aggregation. Kudzu tested separately also inhibited adenosine phosphate (ADP)–induced platelet aggregation ex vivo, while neither the formula nor kudzu alone affected plasma clotting times. However, the formula did protect mice from death caused by pulmonary thrombosis.<sup>32</sup>

A Chinese decoction containing kudzu (*xuefu zhuyu*) promoted microcirculation and reperfusion in rabbits with acute spinalcord damage. The formula also reduced edema, indicating a protective effect on damaged spinal cords.<sup>33</sup> Another Chinese formula (*wulong dan*, also containing kudzu) had a protective effect on neuronal injury and apoptosis caused by local cerebral ischemia in rats.<sup>34</sup>

Puerarin increased cerebral blood flow in dogs, and attenuated cerebral and spinal cord injuries resulting from ischemia in rats and rabbits. In a rat model of cerebral ischemia, puerarin (100 mg per kg intraperitoneally) decreased the infarct volume by 34 percent and improved neurologic functions. Puerarin also significantly reduced apoptosis and necrosis in the cortex.<sup>35</sup>

Poststroke depression is a common and severe complication. Kudzu (75, 150, or 300 mg per kg) administered orally to mice after cerebral ischemia reperfusion reversed the resulting low levels of a metabolite of dopamine and norepinephrine and alleviated the depressive-like behaviors in the mice.<sup>36</sup> Kudzu has also shown a potential benefit in dementia in animal studies.<sup>18,37,38</sup>

#### **Cardiovascular Benefits**

In China, puerarin injections are widely used to treat coronary heart disease and angina pectoris. A review of clinical trials on unstable angina (N = 1240) showed puerarin to be about as effective as conventional Western treatments, and a combination of puerarin and Western drugs was more effective than the drugs alone. The drugs included isosorbide dinitrate, beta-blockers, cal-

<sup>&</sup>lt;sup>†</sup>The formula, a *shuanggen* cephalocathartic decoction, was dosed at 4 g per kg per day. Nimodipine is used to reduce the incidence and severity of ischemic deficits in subarachnoid hemorrhages.

cium-channel blockers, aspirin, nitroglycerine, and others. The researchers noted that these results should be interpreted with care owing to the very low methodological quality of the studies.<sup>39</sup> In another clinical trial, 500 mg of puerarin administered by venoclysis before anesthesia reduced increases in serum enzymes, indicating that puerarin may prevent myocardial injury caused by anesthesia in patients who have hypertension.<sup>40</sup>

Daidzein was remarkably effective for preventing ventricular fibrillation and arrhythmia in mice and rats. This substance antagonized induced arrhythmia in rabbits and prevented induced ventricular fibrillation and ensuing death in rats.<sup>41</sup>

Studies show that puerarin dilates coronary arteries, relieves spasm, increases coronary blood flow and blood supply to the ischemic area, slowly reduces heart rate, improves myocardial oxygen demand, improves coronary circulation and contractility of the ischemic heart, acts as a safe and potent beta-blocker, suppresses platelet aggregation, lowers blood viscosity, and improves microcirculation.<sup>39,42</sup>

Kudzu and puerarin also have reduced the atherogenic effect of dietary cholesterol in rats and improve cholesterol profiles significantly in vivo and in vitro.<sup>43–46</sup>

Finally, in a study of hospitalized patients with dyslipidemia (N = 120), a formula containing kudzu (*tiaozhi zengshou tang*) was compared with pravastatin (10 mg per day) and a combination of the formula and the drug. The formula and pravastatin had similar effects on total cholesterol, triglycerides, and high-density lipoprotein (HDL) blood levels (81 percent versus 80 percent improvement), while the combination reportedly achieved a 97 percent improvement.<sup>47</sup>

#### Potential for Diabetes Prevention and Treatment

Kudzu also shows potential both to treat diabetes and prevent its complications. Various kudzu formulas are used for this purpose in Asia, but kudzu is not widely used in diabetes in Western practice. No clinical trials were located on this use of kudzu, but both animal and in vitro studies suggest that practitioners should consider its potential benefits for people with diabetes.

Some kudzu-containing herbal formulas have been studied in animals. A compound known as *lian zhu* improved blood sugar, glycosylated hemoglobin, urinary protein, and various other parameters in rats with diabetes.<sup>48</sup> Another formula, *Shinomittel*, did not reduce elevated blood sugar levels in rats with diabetes but did have a synergistic effect on blood sugar levels when combined with insulin.<sup>49</sup>

In addition, isolated constituents of kudzu have shown positive effects in animals and in vitro. Puerarin dose-dependently decreased plasma glucose concentrations in rats with diabetes and also somewhat reduced glucose levels in normal rats. In isolated soleus muscle from rats with diabetes, puerarin enhanced the uptake of glucose dose-dependently, suggesting that puerarin may increase glucose utilization and lower plasma glucose in rats who are diabetic and lack insulin.<sup>50</sup>

In vitro studies show that puerarin may protect islet cells effectively from the toxic action of reactive oxygen species (ROS) in diabetes.<sup>51</sup> Puerarin has also decreased lens epithelium cell

### Kudzu Blossom Jelly

#### Ingredients

- 4 cups of kudzu<sup>a</sup> blossoms
- 4 cups of water
- I tablespoon of lemon juice
- I pectin package
- 5 cups of sugar

#### Preparation

Make kudzu blossom tea and allow it to sit overnight. Strain flowers. Bring the tea to a boil. Add sugar and pectin (while stirring constantly) and bring to a full rolling boil for I minute. Remove mixture from heat and skim off the foam. Pour hot jelly into clean jars and process in a hot water bath for 5 minutes.

<sup>a</sup>Latin binomial is *Pueraria montana*.

apoptosis in rats with diabetes, indicating a potential use in the prevention of diabetes-induced cataracts.<sup>52</sup> In diabetes, most patients have both atherogenic lipid abnormalities and insulin resistance.

Compounds that target the peroxisome proliferators-activated receptors (PPARs) can correct these problems and kudzu, in a bioassay, activated PPARs significantly.<sup>53</sup> Kaikasaponin III from kudzu flowers showed antithrombosis activity in rats with diabetes; there are also indications that the substance may have hypoglycemic and hypolipidemic effects by moderating phase I and II enzyme activities.<sup>54</sup> In another study, tectorigenin produced similar in vitro effects on phase I and II enzyme activities as did the drug glibenclamide.<sup>55</sup>

### Hepatoprotective Effects

As mentioned above, kudzu has long been used to mitigate the damage alcohol can inflict on the body, particularly on the liver. Preliminary studies show that kudzu has a hepatoprotective action. Nine kudzu saponins have shown hepatoprotective activity.<sup>56</sup> Their ability to inhibit the elevation of alanine aminotransferase was stronger than that of glycyrrhizin, which was used as a positive control.<sup>57</sup> The crude saponins from kudzu flowers were also found to be effective for ameliorating experimentally induced liver injury.<sup>58</sup> Kakkalide (100 mg per kg) administered orally to mice with induced liver injury had a more potent hepatoprotective effect than did silybin, a compound found in *Silybum marianum* (milk thistle), a well-established hepatoprotectant.<sup>59</sup>

An extract of kudzu flowers provided significant protection against carbon tetrachloride–induced damage in rats,<sup>60</sup> and tectorigenin had a greater inhibitory effect on increases in liver enzymes than did dimethyl diphenyl bicarboxylate, which is used as a commercial hepatoprotective agent.<sup>61</sup>

Puerarin administered to rats with liver fibrosis significantly increased apoptosis of activated hepatic stellate cells, which indicates that puerarin may be able to reverse induced liver fibrosis in rats.<sup>62</sup> In a similar experiment, a formula containing kudzu (*quinggan huoxuefan*) obviously reduced liver fibrosis and

normalized all liver enzymes tested.<sup>63</sup> In rats with fatty livers, formulas containing kudzu significantly modified indicators of the onset of fatty liver disease in the animals.<sup>64–66</sup>

#### **Other Potential Benefits**

Kudzu and its constituents and metabolites (puerarin, tectorigenin) have shown cytotoxic activity against various cancer-cell lines.<sup>67,68</sup> The flavonoids of *P. Montana*, which showed significant antimutagenicity in the Ames test with kaikasaponin III, having the most potent action.<sup>69</sup>

In an asthmatic rat model, puerarin administered intragastrically improved a number of parameters involved in the onset of asthma.<sup>70</sup> Tectorigenin inhibited the passive cutaneous anaphylaxis reaction potently and inhibited the effects induced by immunoglobulin E (IgE).<sup>71</sup> Daidzein has inhibited potently the passive cutaneous anaphylaxis reaction in mice.<sup>72</sup>

One of kudzu's traditional uses is to reduce fever. Kudzu's glycosides (daidzin and genistin) had a significant antipyretic effect on lipopolysaccharide (LPS)–induced fever in mice.<sup>73</sup> In a screening of 170 plants used in Korean herbal medicine, kudzu had one of the strongest antioxidant actions in vitro.<sup>74</sup> Other studies have confirmed that the plant has significant antioxidant activity.<sup>75–77</sup> Kudzu also has an anti-inflammatory effect that may be useful for treating osteoarthritis.<sup>78,79</sup> Finally, the plant showed a potential benefit in a rat model of preeclampsia.<sup>80</sup>

## Safety of Kudzu

Puerarin is the major isoflavone found in kudzu. Puerarin is rapidly absorbed and has reached peak levels at 2 hours with a half-life of approximately 4.3 hours in healthy volunteers. The elimination half-life was not significantly altered by repeated administration. As accumulation will not occur, and plasma levels remain at biologically active levels for even 8 hours after the last steady-state dose, three times per day dosing is recommended.<sup>81</sup>

Kudzu is used in cooking and generally is considered to be very safe.<sup>82</sup> However, both *P. montana* extract and puerarin show a complex effect on different cytochrome p450 isoforms. Puerarin induces CYP 2A1, 1A1/2, 3A1, and 2C11, while kudzu itself induces CYP 1A2, 3A1, and 2B1. Both have inactivated CYP 3A, 2E1, and 2B1, suggesting a potential for drug interactions.<sup>76</sup> In rats given a *P. montana* extract intragastrically, a loss of approximately 50 percent of both total p450 content and CYP-2E1-dependent p-nitrophenol hydroxylase activity was observed in purified hepatic microsomes. At the same time, a threefold increase in NADPH CYP-reductase activity was recorded.<sup>75</sup>

In rats, a kudzu decoction had a significant effect on the metabolism of the drug methotrexate and, when combined with the drug, resulted in surprisingly high mortality rates (14.3 percent and 57.1 percent, respectively). When methotrexate was given intravenously, its half-life was increased by 53.9 percent, and its clearance was decreased by 47.9 percent.<sup>83</sup> This shows that caution is needed when combining kudzu with other drugs.

However, as mentioned above, kudzu and puerarin are commonly used in China in combination with a variety of drugs to treat stroke and heart conditions.

The information on the reproductive safety of kudzu is sparse, but there are indications that its estrogenic effect may be undesirable in premenopausal females and in male animals. In a study, *P. mirifica* increased menstrual-cycle length significantly in monkeys, and, at a high dose (1000 mg per day) the animals' cycle disappeared entirely and did not return to normal after discontinuation of the regimen. The researchers surmised that ovulation may have been suppressed by a lowering of gonadotropins.<sup>84</sup>

In another study using the same dose regimen, there was a significant increase in lengths of the follicular phase and total menstrual cycle in the high-dose group, but no change occurred when using the lower doses. Gonadotropin levels did not change during the first and second menstrual cycles of the post-treatment period. However, the highest dose disturbed ovarian function and menstrual cycle in the monkeys.<sup>85</sup>

*P. tuberosa* administered to rats postcoitally caused a hypertrophy of corpora lutea and the animals' uterine histoarchitecture appeared to be nonreceptive on the day of implantation.<sup>86</sup> However, common blood values were not affected by this treatment and kudzu was deemed to be safe in rats at these acute and subacute dosage regimens.<sup>87</sup>

In male rats, *P. tuberosa* root (100 mg per day) reduced the weights of testes, epididymis, seminal vesicle, and ventral prostate. Sperm motility was reduced significantly and the treatment reduced the fertility of male rats by 100 percent.<sup>88</sup> However, in gonadectomized rats, kudzu normalized gonadotropin levels after 1 week in males and after 2 weeks in females. In male rats on the highest dose, epididymis weight increased.<sup>89</sup>

In one study, daidzein and puerarin had no effect on LH levels but, at a high dose, increased uterine weights significantly. The researchers concluded that these compounds would be unlikely to alleviate vasomotor symptoms in postmenopausal women but, owing to the compounds' uterotropic effects, at high doses, might increase the risk of endometrial hyperplasia.<sup>90</sup> Other clinical studies discussed above, however, did show a benefit on such symptoms in women.

These studies combine to show that reproductive health should be monitored when kudzu is given to men and women in their reproductive years.

There are no reported adverse effects from the use of kudzu in humans. In China, puerarin is often administered by injection. There are reports of patients experiencing fever, allergy, skin reaction, hemolysis, and injury to kidney or liver after taking puerarin intramuscularly or intravenously.<sup>39</sup>

Kudzu has been shown to absorb heavy metals (copper, cadmium and zinc) effectively from the soil while growing.<sup>91</sup> Thus, a clean source for the herb is important.

## Conclusions

Kudzu is a plant with remarkable properties that Western botanical medicine is just beginning to utilize. Its multitude of potential uses ranging from diabetes to stroke and cardiac ailments deserves greater investigation both in research and in clinical use.  $\hfill \Box$ 

#### References

**1.** No author listed. The Amazing Story of Kudzu Love It, Or Hate It. . . . It Grows On You! The University of Alabama Center for Public Television and Radio. www.alabamatv.org/kudzu/ February 14, 2007.

**2.** Jiang R-W, Lau K-M, Lam H-M, et al. A comparative study on aqueous root extracts of *Pueraria thomsonii* and *Pueraria lobata* by antioxidant assay and HPLC fingerprint analysis. J Ethnopharmacol 2005;96(1–2):133–138.

**3.** Kang SC, Lee CM, Choi H, et al. Evaluation of Oriental medicinal herbs for estrogenic and antiproliferative activities. Phytother Res 2006;20:1017–1019.

**4.** Park EK, Shin J, Bae EA, et al. Intestinal bacteria activate estrogenic effect of main constituents puerarin and daidzin of *Pueraria thunbergiana*. Biol Pharmaceut Bull 2006;29:2432–2435.

**5.** Shin JE, Bae EA, Lee YC, et al. Estrogenic effect of main components kakkalide and tectoridin of *Puerariae flos* and their metabolites. Biol Pharmaceut Bull 2006;29:1202–1206.

**6.** Shebek J, Rinbone JP. A pilot study exploring the effect of kudzu root on the drinking habits of patients with chronic alcoholism. J Altern Complement Med 2000;6:45–48.

7. Overstreet DH, Keung W-M, Rezvani AH, et al. Herbal remedies for alcoholism: Promises and possible pitfalls. Alcohol Clin Exp Res 2003;27:177–185.
8. Lukas SE, Penetar D, Berko J, et al. An extract of the Chinese herbal root kudzu reduces alcohol drinking by heavy drinkers in a naturalistic setting. Alcohol Clin Exp Res 2005;29:756–762.

**9.** Rezvani AH, Overstreet DH, Perfumi M, Massi M. Plant derivatives in the treatment of alcohol dependency. Pharmacol Biochem Behav 2003;75:593–606.

**10.** Lin RC, Li T-K. Effects of isoflavones on alcohol pharmacokinetics and alcohol-drinking behavior in rats. Am J Clin Nutr 1998;68(6suppl): 1512S–1515S.

**11.** Lin RC, Guthrie S, Xie C-Y, et al. Isoflavonoid compounds extracted from *Pueraria lobata* suppress alcohol preference in a pharmacogenetic rat model of alcoholism. Alcoholism: Clin Exp Res 1996;20:659–663.

**12**. Benlhabib E, Baker JI, Keyler DE, Singh AK. Kudzu root extract suppresses voluntary alcohol intake and alcohol withdrawal symptoms in P rats receiving free access to water and alcohol. J Med Food 2004;7: 168–179.

**13.** Lee J-S. Supplementation of *Pueraria radix* water extract on changes in antioxidant enzymes and lipid profile in ethanol-treated rats. Clinica Chimica Acta 2004;347(1–2):121–128.

**14.** Jang M-H, Shin M-C, Lee T-H, et al. Effect of *Puerariae radix* on c-Fos expression in hippocampus of alcohol-intoxicated juvenile rats. Biol Pharmaceut Bull 2003;26:37–40.

**15.** Yamazaki T, Hosono T, Matsushita Y, et al. Pharmacological studies on *Puerariae flos* IV: Effects of *Pueraria thomsonii* dried flower extracts on blood ethanol and acetaldehyde levels in humans. Int J Clin Pharmacol Res 2002;22:23–28.

**16.** Li WZ, Lu J, Sun XY, et al. Studies on the effect of extracts of several Chinese herbal medicines and other medicines on alcohol dehydrogenase activity [in Chinese]. Zhong Yao Cai 2006;29:816–818.

**17.** Han P, Li J, Li WJ, et al. Potential antiviral drug pueraria crude extract and puerarin protect against ethanol-induced cytotoxicity in embryonic mouse hippocampal cultures [in Chinese]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2005;19:244–247.

**18.** Yamazaki T, Yaguchi M, Nakajima Y, et al. Effects of an aqueous extract of *Puerariae flos* (Thomsonide) on impairment of passive avoidance behavior in mice. J Ethnopharmacol 2005;100:244–248.

**19.** Lukaczer D, Darland G, Tripp M, et al. Clinical effects of a proprietary combination isoflavone nutritional supplement in menopausal women: A pilot trial. Alt Ther Health Med 2005;11:60–65.

**20.** Lamlertkittikul S, Chandeying V. Efficacy and safety of *Pueraria mirifica* (*Kwao Kruea Khao*) for the treatment of vasomotor symptoms in perimenopausal women: Phase II study. J Med Assoc Thailand 2004;87:33–40.

**21.** Woo J, Lau E, Ho SC, et al. Comparison of *Pueraria lobata* with hormone replacement therapy in treating the adverse health consequences of menopause. Menopause 2003;10:352–361.

**22.** Xu X, Hu Y, Ruan Q. Effects of puerarin on learning-memory and amino acid transmitters of brain in ovariectomized mice. Planta Med 2004;70:627–631.

**23.** Trisomboon H, Malaivijitnond S, Watanabe G, et al. The estrogenic effect of *Pueraria mirifica* on gonadotrophin levels in aged monkeys. Endocrine 2006;29:129–134.

**24.** Trisomboon H, Malaivijitnond S, Suzuki J, et al. Long-term treatment effects of *Pueraria mirifica* phytoestrogens on parathyroid hormone and calcium levels in aged menopausal Cynomolgus monkeys. J Reprod Dev 2004;50:639–645.

**25.** Wang X, Wu J, Chiba H, et al. *Puerariae radix* prevents bone loss in ovariectomized mice. J Bone Mineral Metabol 2003; 21:268–275.

**26.** Zhang HM, Chen JC, Liu YH, Wang KZ. Experimental study of the effects of puerarin on biological characters of osteoblasts in vitro [in Chinese]. Zhongguo Zhong Yao Za Zhi 2005; 30:1947–1949.

**27.** Huh JE, Yang HR, Park DS, et al. *Puerariae radix* promotes differentiation and mineralization in human osteoblast-like SaOS-2 cells. J Ethnopharmacol 2006;104:345–350.

**28.** Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: A preliminary estimate. Cerebrovasc Dis 2003;16:280–285.

**29.** Wang C, Zhao X, Mao S, et al. Management of SAH with Traditional Chinese Medicine in China. Neurol Res 2006;28:436–444.

**30.** Wu H-X, Cai J-W, Xiang H-B, Lin L. Effects of *shuanggen* cephalocathartic decoctum on model rats with vascular dementia in behavioristics. Zhongguo Linchuang Kangfu [Chin J Clin Rehabil] 2006;10:180–182.

**31.** Tan Y, Liu M, Wu B. Clinical efficacy of pueraria for acute cerebral infarction. [in Chinese]. Chin J Evidence-Based Med 2006;6:494–499.

**32.** Park E-K, Han Y-O, Han MJ, Kim D-H. Antithrombosis of *Chungpesagantang* and its ingredients. Nat Prod Sci 2004;10:109–113.

**33.** Liu R-Z, Pan H-S, Tang H-J, et al. Effect of *Xuefu Zhuyu* decoction on neurons and vascular perfusion in rabbits after decompression of acute cervical spinal cord damage in an early time [in Chinese]. Zhongguo Linchuang Kangu 2006;10:53–55.

**34.** Guo J-S, Peng K, Zang K-T, et al. Effect of *wulong dan* on apoptotic neuron and its related genetic expression in rats with focal cerebral ischemia [in Chinese]. Zhongguo Linchuang Kangfu 2006;10:44–46.

**35.** Xu X, Zhang S, Zhang L, et al. The neuroprotection of puerarin against cerebral ischemia is associated with the prevention of apoptosis in rats. Planta Med 2005;71:585–591.

**36.** Yan B, Wang D-Y, Xing D-M, et al. The antidepressant effect of ethanol extract of *Radix puerariae* in mice exposed to cerebral ischemia reperfusion. Pharmacol Biochem Behav 2004;78:319–325.

**37.** Heo HJ, Suh YM, Kim MJ, et al. Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia. Biosci Biotechnol Biochem 2006;70:107–111.

**38.** Hsieh M-T, Kuo L-H, Tsai F-H, et al. Effects of puerarin on scopolamine-, mecamylamine-, p-chloroamphetamine- and dizocilpineinduced inhibitory avoidance performance impairment in rats. Planta Med 2002;68:901–905.

**39.** Wang Q, Wu T, Chen X, et al. Puerarin injection for unstable angina pectoris. Cochrane Database Syst Rev 2006;19:CD004196.

**40.** Wu XP, Feng JG, Chen HM, et al. Protective effects of puerarin against myocardial injury in patients with hypertension during perioperational period [in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zie 2006;26:255–257.

**41.** Ye HY, Qui F, Zeng J, et al. Effect of daidzein on antiarrhythmia [in Chinese]. Zhongguo Zhong Yao Za Zhi 2003;28:853–856.

**42.** Gao Q, Pan HY, Xia Q, Bruce I. Improvement of ventricular mechanical properties by puerarin involves mitochondrial permeability transition in isolated rat heart during ischemia and reperfusion. Conf Proc IEEE Eng Med Biol Soc 2005;6:5591–5594.

**43.** Yan L-P, Chan S-W, Chan AS-C, et al. Puerarin decreases serum total cholesterol and enhances thoracic aorta endothelial nitric oxide synthase expression in diet-induced hypercholesterolemic rats. Life Sci 2006; 79:324–330.

**44**. Lee JS, Mamo J, Ho N, Pal S. The effect of *Puerariae radix* on lipoprotein metabolism in liver and intestinal cells. BMC Complement Altern Med 2002;2:7.

**45.** Wattanapitayakul SK, Chularojmontri L, Srichirat S. Effects of *Pueraria mirifica* on vascular function of ovariectomized rabbits. J Med Assoc Thai 2005;88(supp1):S21–S29.

**46.** Guan L, Yeung SY, Huang Y, Chen ZY. Both soybean and kudzu phytoestrogens modify favorably the blood lipoprotein profile in ovariectomized and castrated hamsters. J Agric Food Chem 2006;54:4907–4912.

**47.** Wang Z-K, Wang F-W, Wang G-Y. Observation of effects of *tiaozhi zengshou tang* on regulation of dyslipidemia. Zhongguo Linchuang Kang-fu 2005;9:183–185.

**48.** Duan W, Gong H, Wang J, et al. Preventing and treating actions of compound *Lian Zhu* capsule on micrangium lesions in diabetic rats. J Trad Chin Med 2005;25:148–152.

**49.** Yamaguchi K, Iwasaki S, Shimizu M, et al. Improving effects of a product containing crude drugs including coptis rhizome, rehmannia root and ginseng on metabolic disorder in streptozotocin-induced diabetic rats. Pharmacometrics 1996;52:417–423.

**50.** Hsu F-L, Liu I-M, Kuo D-H, et al. Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats. J Nat Prod 2003;66:788–792.

**51.** Xion FL, Sun XH, Gan L, et al. Puerarin protects rat pancreatic islets from damage by hydrogen peroxide. Eur J Pharmacol 2006; 529(1–3):1–7.

**52.** Hao LN, Ling YQ, Luo XM, et al. Puerarin decreases lens epithelium cell apoptosis induced partly by peroxynitrite in diabetic rats [abstr]. Sheng Li Xue Bao 2006;58:584–592.

**53.** Shen P, Liu MH, Ng TY, et al. Differential effects of isoflavones, from *Astragalus membranaceus* and *Pueraria thomsonii*, on the activation of PPARa, PPARgamma, and adipocyte differentiation in vitro. J Nutr 2006;136:899–905.

**54.** Choi J, Shin MH, Park K-Y, et al. Effect of kaikasaponin III obtained from *Pueraria thunbergiana* flowers on serum and hepatic lipid peroxides and tissue factor activity in the streptozotocin-induced diabetic rat. J Med Food 2004;7:31–37.

**55.** Choi J, Shin M-H, Park K-Y, et al. Effect of tectorigenin obtained from *Pueraria thunbergiana* flowers on phase I and II enzyme activities in strep-tozotocin- induced diabetic rat. Nat Prod Sci 2003;9:235–240.

**56.** Arao T, Udayama M, Kinjo J, Nohara T. Preventive effects of saponins from the *Pueraria lobata* root on in vitro immunological liver injury of rat primary hepatocyte cultures. Planta Med 1998;64:413–416.

**57.** Arao T, Udayama M, Kinjo J, et al. Preventive effects of saponins from *Puerariae radix* (the root of *Pueraria lobata* OHWI) on in vitro immunological injury of rat primary heptocyte cultures. Biol Pharmaceut Bull 1997;20:988–991.

**58.** Kinjo J. Studies on bioactive compounds from leguminous plants structures, activities, HPLC profiles and functional importance of sugar moiety for oleanene glucuronides. Nat Med 1996;50:79–85.

**59.** Lee HU, Bae EA, Kim DH. Hepatoprotective effects of irisolidone on tert-butyl hyperoxide-induced liver injury. Biol Pharm Bull 2005;28: 531–533.

**60.** Shukla S, Jonathan S, Sharma A. Protective action of butanolic extract of *Pueraria tuberosa* DC. against carbon tetrachloride induced hepatotoxicity in adult rats. Phytother Res 1996;10:608–609.

**61.** Lee H-W, Choo M-K, Bae E-A, Kim D-H. Beta-glucuronidase inhibitor tectorigenin isolated from the flower of *Pueraria thunbergiana* protects carbon tetrachloride induced liver injury. Liver Int 2003;23:221–226.

**62.** Zhang S, Ji G, Liu J. Reversal of chemical-induced liver fibrosis in Wistar rats by puerarin. J Nutr Biochem 2006;17:485–491.

**63.** Ji G, Wang L, Zhang S-H, et al. Effect of Chinese medicine *Qinggan Huoxuefang* on inducing HSC apoptosis in alcoholic liver fibrosis rats [abstr]. World J Gastroenterol 2006;12:2047–2052.

**64.** Hyun KJ, Sun HH, Se YC. Traditional Chinese Medicine improves dysfunction of peroxisome proliferator-activated receptor a and microsomal triglyceride transfer protein on abnormalities in lipid metabolism in ethanol-fed rats. Biofactors 2005;23:163–176.

**65.** Kwon H-J, Kim Y-Y, Choung S-Y. Amelioration effects of Traditional Chinese Medicine on alcohol-induced fatty liver. World J Gastroenterol 2005;11:5512–5516.

**66.** Hyum JK, Kim Y-Y, Se YC. Effects of natural product extract on the fatty liver induced by alcohol diet in rats. J Health Sci 2004;50:466–473. **67.** Yu Z, Li W. Induction of apoptosis by puerarin in colon cancer HT-29

cells. Cancer Lett 2006;238:53–60.

**68.** Lee K-T, Sohn I-C, Kim Y-K, et al. Tectorigenin, an isoflavone of *Pueraria thunbergiana* BENTH. induces differentiation and apoptosis in human promyelocytic leukemia HL-60 cells. Biol Pharmaceut Bull 2001;24: 1117–1121.

**69.** Park KY, Jung GO, Choi J, et al. Potent antimutagenic and their antilipid peroxidative effect of kaikasaponin III and tectorigenin from the flower of *Pueraria thunbergiana*. Arch Pharm Res 2002;25:320–324.

**70.** Song S-Z, Tian Y-P, Wang C-B, et al. Preventive effects of pueraria flavonoid in experimental asthmatic rats [in Chinese]. Zhongguo Linchuang Kangfu 2005;9:129–131.

**71.** Park E-K, Shin Y-W, Lee H-U, et al. Passive cutaneous anaphylaxisinhibitory action of tectorigenin, a metabolite of tectoridin by intestinal microflora. Biol Pharmaceut Bull 2004;27:1099–1102.

**72.** Choo M-K, Park E-K, Yoon H-K, Kim DH. Antithrombotic and antiallergic activities of daidzein, a metabolite of puerarin and daidzin produced by human intestinal microflora. Biol Pharmaceut Bull 2002;25: 1328–1332.

**73.** Yasuda T, Endo M, Kon-no T, et al. Antipyretic, analgesic and muscle relaxant activities of pueraria isoflavonoids and their metabolites from *Pueraria lobata* Ohwi—a traditional Chinese drug. Biol Pharmaceut Bull 2005;28:1224–1228.

**74.** Kyung AN, Sang KL. Evaluation of the antioxidant potential of natural products mediated by inhibition of xanthine oxidase activity. Nat Prod Sci 1999;5:165–171.

**75.** Speroni E, Guerra MC, Rossetti A, et al. Antioxidant activity of *Pueraria lobata* (Willd) in the rat. Phytother Res 1996;10(suppl1):S95–S97.

**76.** Guerra MC, Speroni E, Broccoli M, et al. Comparison between Chinese medical herb *Pueraria lobata* crude extract and its main isoflavone puerarin: Antioxidant properties and effects on rat liver CYP-catalysed drug metabolism. Life Sci 2000;67:2997–3006.

77. Cha BC, Lee EH, Cho JY. Glutathione S-transferase activity and hyaluronidase inhibitory effect of medicinal plants [in Korean]. Korean J Pharmacogn 2004;35:184–188.

**78.** Kwon SY, Lee HS, Lee SH, et al. Analgesic effect and inhibition of prostaglandin  $E_2$  activity and pro-inflammatory cytokines production by ethyl alcohol extract from new herbal formula [in Korean]. Korean J Pharmacogn 2006;37:136–142.

**79.** Jeon YJ, Li MH, Lee KY, et al. KIOM-79 inhibits LPS-induced iNOS gene expression by blocking NF-kappaB/Rel and p38 kinase activation in murine macrophages. J Ethnopharmacol 2006;108:38–45.

**80.** Wang C, Wang XY, Zhou S, Xiong Q. Therapeutic effect of puerarin on rats with pre-eclampsia [in Chinese]. Zhonghua Fu Chan Ke Za Zhi 2006;41:118–120.

**81.** Penetar DM, Teter CJ, Ma Z, et al. Pharmacokinetic profile of the isoflavone puerarin after acute and repeated administration of a novel kudzu extract to human volunteers. J Altern Complement Med 2006;12:543–548.

**82.** McGuffin M, Hobbs C, Upton R, Goldberg A. American Herbal Products Botanical Safety Handbook. Boca Raton, FL: CRC Press, 1997.

**83.** Chiang H-M, Fang S-H, Wen K-C, et al. Life-threatening interaction between the root extract of *Pueraria lobata* and methotrexate in rats. Toxicol Appl Physiol 2005;209:263–268.

**84.** Trisomban H, Malaivijitnond S, Watanabe G, Taya K. Ovulation block by *Pueraria mirifica*: A study of its endocrinological effect in female monkeys. Endocrine 2005;26:33–39.

**85.** Trisomboon H, Malaivijitnond S, Watanabe G, Taya K. Estrogenic effects of *Pueraria mirifica* on the menstrual cycle and hormone-related ovarian functions in cyclic female Cynomolgus monkeys. J Pharmacol Sci 2004;94:51–59.

**86.** Shukla S. Post-coital contraceptive action of *Pueraria tuberosa* DC Extract in rats. Phytother Res 1996;10:95–99.

**87.** Shukla S. Toxicological studies of *Pueraria tuberosa*, a potent antifertility plant. Int J Pharmacog 1995;33:324–329.

**88.** Gupta RS, Sharma R, Sharma A, et al. Antifertility effects of *Pueraria tuberosa* root extract in male rats [abstr]. Pharmaceut Biol 2004;42:603–609.

**89.** Malaivijitnond S, Kiatthaipipat P, Chershewasart W, et al. Different effects of *Pueraria mirifica*, a herb containing phytoestrogens on LH and FSH secretion in gonadectomized female and male rats. J Pharmacol Sci 2004;96:428–435.

**90.** Rachon D, Vortherms T, Seidlova-Wuttke D, Wuttke W. Dietary daidzein and puerarin do not affect pituitary LH expression but exert uterotropic effects in ovariectomized rats. Maturitas 2007;January 25; e-pub ahead of print.

**91.** Brown PA, Brown JM, Allen SJ. The application of kudzu as a medium for the adsorption of heavy metals from dilute aqueous waste streams. Bioresource Technol 2001;78:195–201.

Kathy Abascal, B.S., J.D., R.H. (AHG), is executive director of the Botanical Medicine Academy, Vashon, Washington. Eric Yarnell, N.D., R.H. (AHG), is president of the Botanical Medicine Academy, a specialty board for using medicinal herbs, and is an adjunct faculty member at Bastyr University, Kenmore, Washington.

To order reprints of this article, write to or call: Karen Ballen, *ALTERNA-TIVE & COMPLEMENTARY THERAPIES*, Mary Ann Liebert, Inc., 140 Huguenot Street, 3rd Floor, New Rochelle NY 10801, (914) 740-2100.